24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study
Entrectinib Meets Objective Response Rate End Point in ROS1+ NSCLC
The safety profile of entrectinib with liquid biopsy in the BFAST study was consistent with prior reports for patients with ROS1-positive NSCLC.
Sacituzumab Govitecan Misses OS End Point in Metastatic NSCLC
The phase 3 EVOKE-01 study found that OS improved numerically, but not statistically significantly, in sacituzumab govitecan vs docetaxel with a similar safety profile.
Afami-cel Earns FDA Accelerated Approval in Unresectable Synovial Sarcoma
Data from SPEARHEAD-1 support the accelerated approval of afamitresgene autoleucel in metastatic or unresectable synovial sarcoma.
Post-HCT Cyclophosphamide Yields Similar Outcomes in GVHD Subgroups
Cyclophosphamide-based prophylaxis for GVHD showed similar outcomes across racial subgroups regardless of matched or mismatched unrelated donors.
FDA Expands Approval for Dostarlimab/Chemo in Advanced Endometrial Cancer
Data from the RUBY trial support the expanded approval of dostarlimab plus chemotherapy in patients with advanced/recurrent endometrial cancer.
Zolbetuximab/Chemo Gets Positive EU CHMP Opinion in Advanced Gastric Cancer
Frontline zolbetuximab plus chemotherapy is one step closer to approval by the European Commission for select patients with advanced gastric/GEJ cancer.
VCN-01 Earns Rare FDA Pediatric Drug Status in Retinoblastoma
Phase 1 data may support the potential activity and safety of VCN-01 among pediatric patients with refractory retinoblastoma.
Breast Cancer Survivors Do Not Undergo Genetic Counseling, Testing Despite Eligibility
Genetic testing may be beneficial post-cancer diagnosis for reducing cancer risk for families with hereditary cancer syndromes and managing treatment.
Hybrid Model of CAR T-Cell Therapy May Help Manage Treatment-Related Infections
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
IMNN-001/Chemo Improves Survival in Advanced Ovarian Cancer
Combining IMNN-001 with chemotherapy also elicited a progression-free survival improvement compared with chemotherapy alone in the OVATION 2 trial.
Updated NCCN Guidelines Recommend Imetelstat for Anemia in Lower-Risk MDS
The guideline update follows the FDA’s approval of imetelstat in patients with lower-risk MDS based on data from the phase 3 IMerge trial.
Secondary Malignancies Risk Still in Question Following CAR T-cell Therapy for Lymphoma
FDA Approves Subcutaneous Daratumumab Regimen in Newly Diagnosed Multiple Myeloma
Data from the PERSEUS trial support the FDA approval of the subcutaneous daratumumab-containing regimen in newly diagnosed multiple myeloma.
BNT111/Cemiplimab Combo Significantly Improves ORR in Unresectable Melanoma
The safety profile of BNT111 plus cemiplimab was consistent with previous trials assessing BNT111 with anti–PD-L1 treatments.
Exercise Oncology May Improve HRQOL in Metastatic RCC
Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.
FDA Grants Priority Review to Asciminib in Newly Diagnosed Ph+ CML
Data from ASC4FIRST support the priority review designation for asciminib in Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.
Study Aims to Address CAR T Accessibility Among Disadvantaged Groups
Survival is Similar With Mismatched vs Matched Unrelated Donors for HCT
Mismatched unrelated donor consideration may expand donor numbers, especially for those with minority ancestry seeking hematopoietic cell transplantation.
Acalabrutinib Combo Significantly Improves PFS Vs Chemoimmunotherapy in CLL
Data from AMPLIFY show a trend towards improved overall survival with acalabrutinib-based therapy among patients with chronic lymphocytic leukemia.
Breast Cancer Hormone-Modulating Therapy May Lower Risk for Dementia
Age and racial differences in subgroup analyses emphasize the need for strategies addressing Alzheimer’s/dementia risk factors and prevention of breast cancer.
FDA Approves Blood Test for Colorectal Cancer Screening
Shield, the first FDA-approved blood test for CRC screening, may offer convenient screening access for those who are at average risk for the disease.
Improving CAR T-Cell Therapy Monitoring Strategies and Access in Lymphoma
Nausheen Ahmed, MD, discusses findings from a study supporting reduced monitoring windows for patients with lymphoma who receive CAR T-cell therapy.
Radiologic Assessment May Be Used Before First Line Therapy for mccRCC
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study
Ubamatamab, Anti-PD-1 ICI, May Bolster Immune Response in Kidney Cancer
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
26 Prediction of Chemotherapy Benefit by MammaPrint® in Patients With HR+HER2- Early-Stage Breast Cancer From Real-World Evidence Studies
SON-080 May Decrease Chemotherapy-Induced Peripheral Neuropathy
The novel drug showed promise in helping to decrease chemotherapy-induced peripheral neuropathy for those who had received prior chemotherapy.
Electronic Intervention May Decrease Low-Value Surgery in Breast Cancer
A user-friendly “nudge” may provide a timely reminder to surgeons to consider the value of sentinel lymph node biopsy in older patients with breast cancer.
FDA Accepts Resubmitted BLA for Cosibelimab in Advanced Skin Cancer
The FDA has set a Prescription Drug User Fee Act date of December 28, 2024, for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.
